Ipsen and Sichuan Biokin Pharmaceutical side by side
Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.
At a glance
Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.
Pipeline by phase
Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.
| Furthest phase | Ipsen | Sichuan Biokin Pharmaceutical |
|---|---|---|
| Phase 1 | Ipsen: 1 of its 9 programs at phase 1
| Sichuan Biokin Pharmaceutical: 8 of its 19 programs at phase 1
and 3 more — sign in to see them all |
| Phase 2 | Ipsen: 4 of its 9 programs at phase 2
| Sichuan Biokin Pharmaceutical: 4 of its 19 programs at phase 2
|
| Phase 3 | Ipsen: 4 of its 9 programs at phase 3
| Sichuan Biokin Pharmaceutical: 7 of its 19 programs at phase 3
and 2 more — sign in to see them all |
| Approved, new studies | 00% | 00% |
Readouts ahead
Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.
| Nov ’26 | Dec | Jan ’27 | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ipsen3 readouts · 1 phase 3 | · | Ipsen, Dec ’26: 1 program whose next study reaches primary completion, 1 in phase 3
| · | · | Ipsen, Mar ’27: 1 program whose next study reaches primary completion
| · | · | · | · | · | · | Ipsen, Oct ’27: 1 program whose next study reaches primary completion
|
| Sichuan Biokin Pharmaceutical8 readouts · 1 phase 3 | Sichuan Biokin Pharmaceutical, Nov ’26: 1 program whose next study reaches primary completion, 1 in phase 3
| Sichuan Biokin Pharmaceutical, Dec ’26: 4 programs whose next study reaches primary completion
| · | Sichuan Biokin Pharmaceutical, Feb ’27: 1 program whose next study reaches primary completion
| · | · | Sichuan Biokin Pharmaceutical, May ’27: 1 program whose next study reaches primary completion
| Sichuan Biokin Pharmaceutical, Jun ’27: 1 program whose next study reaches primary completion
| · | · | · | · |
Changed in the last 90 days
Since Aug 23, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.
Ipsen
New programs 1
- IPN60350phase 2 · first study · Nov 11 · Neoplasm Metastasis
Reached a new phase 0
None
Study stopped 0
None
Primary completion later 1
- corabotasephase 2 · Aug 2026 → Aug 2027 (+12 mo) · moved Oct 6 · NCT04821089
Sichuan Biokin Pharmaceutical
New programs 2
- SI-B037phase 1 · first study · Nov 10
- glecirasibphase 2 · first study · Sep 14 · Carcinoma, Non-Small-Cell Lung
Reached a new phase 0
None
Study stopped 0
None
Primary completion later 1
- izalontamab brengitecanphase 2 · Aug 2026 → Jun 2027 (+10 mo) · moved Oct 9 · NCT06498986
Where they overlap
Conditions where at least two of them have programs: 3 in all. A program counts in each condition its studies name most.
| Condition | Ipsen | Sichuan Biokin Pharmaceutical |
|---|---|---|
| Leukemia, Myeloid, Acuteboth · compare here | Ipsen in Leukemia, Myeloid, Acute: 1 program Their studies: Ipsen’s studies of Leukemia, Myeloid, Acute in search | Sichuan Biokin Pharmaceutical in Leukemia, Myeloid, Acute: 3 programs
Their studies: Sichuan Biokin Pharmaceutical’s studies of Leukemia, Myeloid, Acute in search |
| Hematologic Neoplasmsboth · compare here | Ipsen in Hematologic Neoplasms: 1 program Their studies: Ipsen’s studies of Hematologic Neoplasms in search | Sichuan Biokin Pharmaceutical in Hematologic Neoplasms: 1 program
Their studies: Sichuan Biokin Pharmaceutical’s studies of Hematologic Neoplasms in search |
| Melanomaboth · compare here | Sichuan Biokin Pharmaceutical in Melanoma: 1 program
Their studies: Sichuan Biokin Pharmaceutical’s studies of Melanoma in search |
Same targetBetaPro · free during the beta
Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.
No gene two of them both target, among the programs whose target is known.
What this can't show
- Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
- Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
- Readout dates are the sponsors’ estimates, not results.
- A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
- “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.